Inflammatory bowel disease: exploring gut pathophysiology for novel therapeutic targets

Translational Research

Volumn 176, Issue , 2016, Pages 38-68

  Yadav, Vipul ^a   Varum, Felipe ^b   Bravo, Roberto ^b   Furrer, Esther ^b   Bojic, Daniela ^b   Basit, Abdul W ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b Tillotts Pharma UK Ltd   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; ANTIINFLAMMATORY AGENT; CD98 ANTIGEN; CHEMOKINE RECEPTOR CCR1 ANTAGONIST; CXCL1 CHEMOKINE; ENZYME INHIBITOR; IMMUNOMODULATING AGENT; INTERLEUKIN 1 DERIVATIVE; INTERLEUKIN 13; INTERLEUKIN 18; INTERLEUKIN 21; INTERLEUKIN 6; MICRORNA; NATURAL KILLER CELL RECEPTOR NKG2D; NUTRACEUTICAL; PROBIOTIC AGENT; TRANSCRIPTION FACTOR GATA 3; TUMOR NECROSIS FACTOR INHIBITOR; BIOLOGICAL PRODUCT;

CROHN DISEASE; FECAL MICROBIOTA TRANSPLANTATION; HEREDITY; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOGLOBULIN PRODUCTION; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; ULCERATIVE COLITIS; ANIMAL; DRUG EFFECTS; GASTROINTESTINAL TRACT; GENETICS; INFLAMMATORY BOWEL DISEASES; MICROBIOLOGY; MICROFLORA; MOLECULARLY TARGETED THERAPY; PATHOLOGY;

ANIMALS; BIOLOGICAL PRODUCTS; GASTROINTESTINAL TRACT; HUMANS; INFLAMMATORY BOWEL DISEASES; MICROBIOTA; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION;

EID: 84991387611     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2016.04.009     Document Type: Review

References (270)

1. 1 Hanauer, S.B., Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 12 (2006), S3–S9.
2. 2 Bouma, G., Strober, W., The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 3 (2003), 521–533.
3. 3 Xiao, B., Merlin, D., Oral colon-specific therapeutic approaches toward treatment of inflammatory bowel disease. Expert Opin Drug Deliv 9 (2012), 1393–1407.
4. 4 Katz, J.A., Treatment of inflammatory bowel disease with corticosteroids. Gastroenterol Clin North Am 33 (2004), 171–189 vii.
5. 5 Yadav, V., Varum, F., Bravo, R., Furrer, E., Basit, A.W., Gastrointestinal stability of therapeutic anti-TNF alpha IgG1 monoclonal antibodies. Int J Pharm 502 (2016), 181–187.
6. 6 Zanello, G., Kevans, D., Goethel, A., Silverberg, M., Tyler, A., Croitoru, K., Genetics and innate and adaptive immunity in IBD. Nestle Nutr Inst Workshop Ser 79 (2014), 41–55.
7. 7 Corridoni, D., Arseneau, K.O., Cominelli, F., Inflammatory bowel disease. Immunol Lett 161 (2014), 231–235.
8. 8 Fuss, I.J., Strober, W., The role of IL-13 and NK T cells in experimental and human ulcerative colitis. Mucosal Immunol 1 (2008), S31–S33.
9. 9 Mannon, P.J., Hornung, R.L., Yang, Z., et al. Suppression of inflammation in ulcerative colitis by interferon-beta-1a is accompanied by inhibition of IL-13 production. Gut 60 (2011), 449–455.
10. 10 Okamura, M., Yoh, K., Ojima, M., Morito, N., Takahashi, S., Overexpression of GATA-3 in T cells accelerates dextran sulfate sodium-induced colitis. Exp Anim 63 (2014), 133–140.
11. 11 Ohtani, K., Ohtsuka, Y., Ikuse, T., et al. Increased mucosal expression of GATA-3 and STAT-4 in pediatric ulcerative colitis. Pediatr Int 52 (2010), 584–589.
12. 12 Carlson, M., Raab, Y., Peterson, C., Hallgren, R., Venge, P., Increased intraluminal release of eosinophil granule proteins EPO, ECP, EPX, and cytokines in ulcerative colitis and proctitis in segmental perfusion. Am J Gastroenterol 94 (1999), 1876–1883.
13. 13 Al-Haddad, S., Riddell, R.H., The role of eosinophils in inflammatory bowel disease. Gut 54 (2005), 1674–1675.
14. 14 Makiyama, K., Kanzaki, S., Yamasaki, K., Zea-Iriarte, W., Tsuji, Y., Activation of eosinophils in the pathophysiology of ulcerative colitis. J Gastroenterol 30 (1995), 64–69.
15. 15 Vivinus-Nebot, M., Frin-Mathy, G., Bzioueche, H., et al. Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation. Gut 63 (2014), 744–752.
16. 16 Wedemeyer, J., Vosskuhl, K., Role of gastrointestinal eosinophils in inflammatory bowel disease and intestinal tumours. Best Pract Res Clin Gastroenterol 22 (2008), 537–549.
17. 17 Bischoff, S.C., Grabowsky, J., Manns, M.P., Quantification of inflammatory mediators in stool samples of patients with inflammatory bowel disorders and controls. Dig Dis Sci 42 (1997), 394–403.
18. 18 Cario, E., Bacterial interactions with cells of the intestinal mucosa: Toll-like receptors and NOD2. Gut 54 (2005), 1182–1193.
19. 19 Stoll, M., Corneliussen, B., Costello, C.M., et al. Genetic variation in DLG5 is associated with inflammatory bowel disease. Nat Genet 36 (2004), 476–480.
20. 20 Panwala, C.M., Jones, J.C., Viney, J.L., A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol 161 (1998), 5733–5744.
21. 21 Petronis, A., Petroniene, R., Epigenetics of inflammatory bowel disease. Gut 47 (2000), 302–306.
22. 22 McGovern, D.P., Kugathasan, S., Cho, J.H., Genetics of inflammatory bowel diseases. Gastroenterology 149 (2015), 1163–1176 e2.
23. 23 Loddo, I., Romano, C., Inflammatory bowel disease: genetics, epigenetics, and pathogenesis. Front Immunol, 6, 2015, 551.
24. 24 Loh, G., Blaut, M., Role of commensal gut bacteria in inflammatory bowel diseases. Gut Microbes 3 (2012), 544–555.
25. 25 Serban, D.E., Microbiota in inflammatory bowel disease pathogenesis and therapy: is it all about diet?. Nutr Clin Pract 30 (2015), 760–779.
26. 26 Petersen, H.J., Smith, A.M., The role of the innate immune system in granulomatous disorders. Front Immunol, 4, 2013, 120.
27. 27 Song, E., Jaishankar, G.B., Saleh, H., et al. Chronic granulomatous disease: a review of the infectious and inflammatory complications. Clin Mol Allergy, 9, 2011, 10.
28. 28 Rath, H.C., Schultz, M., Freitag, R., et al. Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect Immun 69 (2001), 2277–2285.
29. 29 Bloom, S.M., Bijanki, V.N., Nava, G.M., et al. Commensal Bacteroides species induce colitis in host-genotype-specific fashion in a mouse model of inflammatory bowel disease. Cell Host Microbe 9 (2011), 390–403.
30. 30 Barnich, N., Carvalho, F.A., Glasser, A.L., et al. CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn disease. J Clin Invest 117 (2007), 1566–1574.
31. 31 Atuma, C., Strugala, V., Allen, A., Holm, L., The adherent gastrointestinal mucus gel layer: thickness and physical state in vivo. Am J Physiol Gastrointest Liver Physiol 280 (2001), G922–G929.
32. 32 Johansson, M.E., Phillipson, M., Petersson, J., Velcich, A., Holm, L., Hansson, G.C., The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Proc Natl Acad Sci U S A 105 (2008), 15064–15069.
33. 33 Dorofeyev, A.E., Vasilenko, I.V., Rassokhina, O.A., Kondratiuk, R.B., Mucosal barrier in ulcerative colitis and Crohn's disease. Gastroenterol Res Pract, 2013, 2013, 431231.
34. 34 Johansson, M.E., Gustafsson, J.K., Holmen-Larsson, J., et al. Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis. Gut 63 (2014), 281–291.
35. 35 Brandtzaeg, P., Induction of secretory immunity and memory at mucosal surfaces. Vaccine 25 (2007), 5467–5484.
36. 36 Takahasi, F., Shah, H.S., Wise, L.S., Das, K.M., Circulating antibodies against human colonic extract enriched with a 40 kDa protein in patients with ulcerative colitis. Gut 31 (1990), 1016–1020.
37. 37 Olson, T.S., Bamias, G., Naganuma, M., et al. Expanded B cell population blocks regulatory T cells and exacerbates ileitis in a murine model of Crohn disease. J Clin Invest 114 (2004), 389–398.
38. 38 Noronha, A.M., Liang, Y., Hetzel, J.T., et al. Hyperactivated B cells in human inflammatory bowel disease. J Leukoc Biol 86 (2009), 1007–1016.
39. 39 Yel, L., Selective IgA deficiency. J Clin Immunol 30 (2010), 10–16.
40. 40 Palm, N.W., de Zoete, M.R., Cullen, T.W., et al. Immunoglobulin A coating identifies colitogenic bacteria in inflammatory bowel disease. Cell 158 (2014), 1000–1010.
41. 41 Khor, B., Gardet, A., Xavier, R.J., Genetics and pathogenesis of inflammatory bowel disease. Nature 474 (2011), 307–317.
42. 42 Matricon, J., Barnich, N., Ardid, D., Immunopathogenesis of inflammatory bowel disease. Self Nonself 1 (2010), 299–309.
43. 43 Ferreira, R.C., Pan-Hammarstrom, Q., Graham, R.R., et al. Association of IFIH1 and other autoimmunity risk alleles with selective IgA deficiency. Nat Genet 42 (2010), 777–780.
44. 44 Macpherson, A., Khoo, U.Y., Forgacs, I., Philpott-Howard, J., Bjarnason, I., Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut 38 (1996), 365–375.
45. 45 Scott, M.G., Nahm, M.H., Macke, K., Nash, G.S., Bertovich, M.J., MacDermott, R.P., Spontaneous secretion of IgG subclasses by intestinal mononuclear cells: differences between ulcerative colitis, Crohn's disease, and controls. Clin Exp Immunol 66 (1986), 209–215.
46. 46 Kobayashi, K., Qiao, S.W., Yoshida, M., Baker, K., Lencer, W.I., Blumberg, R.S., An FcRn-dependent role for anti-flagellin immunoglobulin G in pathogenesis of colitis in mice. Gastroenterology 137 (2009), 1746–1756.e1.
47. 47 Ananthakrishnan, A.N., Environmental risk factors for inflammatory bowel diseases: a review. Dig Dis Sci 60 (2015), 290–298.
48. 48 Parkes, G.C., Whelan, K., Lindsay, J.O., Smoking in inflammatory bowel disease: impact on disease course and insights into the aetiology of its effect. J Crohns Colitis 8 (2014), 717–725.
49. 49 Monteleone, I., MacDonald, T.T., Pallone, F., Monteleone, G., The aryl hydrocarbon receptor in inflammatory bowel disease: linking the environment to disease pathogenesis. Curr Opin Gastroenterol 28 (2012), 310–313.
50. 50 Persson, P.G., Ahlbom, A., Hellers, G., Diet and inflammatory bowel disease: a case-control study. Epidemiology 3 (1992), 47–52.
51. 51 Reif, S., Klein, I., Lubin, F., Farbstein, M., Hallak, A., Gilat, T., Pre-illness dietary factors in inflammatory bowel disease. Gut 40 (1997), 754–760.
52. 52 Roediger, W.E., Moore, J., Babidge, W., Colonic sulfide in pathogenesis and treatment of ulcerative colitis. Dig Dis Sci 42 (1997), 1571–1579.
53. 53 Korzenik, J.R., Past and current theories of etiology of IBD: toothpaste, worms, and refrigerators. J Clin Gastroenterol 39 (2005), S59–S65.
54. 54 Smart, A.L., Gaisford, S., Basit, A.W., Oral peptide and protein delivery: intestinal obstacles and commercial prospects. Expert Opin Drug Deliv 11 (2014), 1323–1335.
55. 55 McConnell, E.L., Fadda, H.M., Basit, A.W., Gut instincts: explorations in intestinal physiology and drug delivery. Int J Pharm 364 (2008), 213–226.
56. 56 Nugent, S.G., Kumar, D., Rampton, D.S., Evans, D.F., Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs. Gut 48 (2001), 571–577.
57. 57 Ewe, K., Schwartz, S., Petersen, S., Press, A.G., Inflammation does not decrease intraluminal pH in chronic inflammatory bowel disease. Dig Dis Sci 44 (1999), 1434–1439.
58. 58 Press, A.G., Hauptmann, I.A., Hauptmann, L., et al. Gastrointestinal pH profiles in patients with inflammatory bowel disease. Aliment Pharmacol Ther 12 (1998), 673–678.
59. 59 Sinha, A., Ball, D.J., Connor, A.L., Nightingale, J., Wilding, I.R., Intestinal performance of two mesalamine formulations in patients with active ulcerative colitis as assessed by gamma scintigraphy. Pract Gastrotenterol 27 (2003), 56–69.
60. 60 Fallingborg, J., Pedersen, P., Jacobsen, B.A., Small intestinal transit time and intraluminal pH in ileocecal resected patients with Crohn's disease. Dig Dis Sci 43 (1998), 702–705.
61. 61 Hebden, J.M., Blackshaw, P.E., Perkins, A.C., Wilson, C.G., Spiller, R.C., Limited exposure of the healthy distal colon to orally-dosed formulation is further exaggerated in active left-sided ulcerative colitis. Aliment Pharmacol Ther 14 (2000), 155–161.
62. 62 Sartor, R.B., Microbial influences in inflammatory bowel diseases. Gastroenterology 134 (2008), 577–594.
63. 63 Willing, B.P., Dicksved, J., Halfvarson, J., et al. A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology 139 (2010), 1844–1854.e1.
64. 64 Sokol, H., Pigneur, B., Watterlot, L., et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 105 (2008), 16731–16736.
65. 65 Jung, Y., Kim, Y.M., What should be considered on design of a colon-specific prodrug?. Expert Opin Drug Deliv 7 (2010), 245–258.
66. 66 Im, E., Riegler, F.M., Pothoulakis, C., Rhee, S.H., Elevated lipopolysaccharide in the colon evokes intestinal inflammation, aggravated in immune modulator-impaired mice. Am J Physiol Gastrointest Liver Physiol 303 (2012), G490–G497.
67. 67 Horrigan, F.D., Danovitch, S.H., The origin of human fecal alkaline phosphatase. Am J Dig Dis 19 (1974), 603–608.
68. 68 Tuin, A., Poelstra, K., de Jager-Krikken, A., et al. Role of alkaline phosphatase in colitis in man and rats. Gut 58 (2009), 379–387.
69. 69 McGuckin, M.A., Eri, R., Simms, L.A., Florin, T.H., Radford-Smith, G., Intestinal barrier dysfunction in inflammatory bowel diseases. Inflamm Bowel Dis 15 (2009), 100–113.
70. 70 Hollander, D., Vadheim, C.M., Brettholz, E., Petersen, G.M., Delahunty, T., Rotter, J.I., Increased intestinal permeability in patients with Crohn's disease and their relatives. A possible etiologic factor. Ann Intern Med 105 (1986), 883–885.
71. 71 Ramasundara, M., Leach, S.T., Lemberg, D.A., Day, A.S., Defensins and inflammation: the role of defensins in inflammatory bowel disease. J Gastroenterol Hepatol 24 (2009), 202–208.
72. 72 Secondulfo, M., de Magistris, L., Fiandra, R., et al. Intestinal permeability in Crohn's disease patients and their first degree relatives. Dig Liver Dis 33 (2001), 680–685.
73. 73 Wehkamp, J., Salzman, N.H., Porter, E., et al. Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci U S A 102 (2005), 18129–18134.
74. 74 McAulfy, R.L., Sommers, S.C., Mast cells in nonspecific ulcerative colitis. Am J Dig Dis 6 (1961), 233–236.
75. 75 Dvorak, A.M., Dickersin, G.R., Crohn's disease: transmission electron microscopic studies. I. Barrier function. Possible changes related to alterations of cell coat, mucous coat, epithelial cells, and Paneth cells. Hum Pathol 11 (1980), 561–571.
76. 76 Tirosh, B., Khatib, N., Barenholz, Y., Nissan, A., Rubinstein, A., Transferrin as a luminal target for negatively charged liposomes in the inflamed colonic mucosa. Mol Pharm 6 (2009), 1083–1091.
77. 77 Liu, X., Ye, L., Christianson, G.J., Yang, J.Q., Roopenian, D.C., Zhu, X., NF-kappaB signaling regulates functional expression of the MHC class I-related neonatal Fc receptor for IgG via intronic binding sequences. J Immunol 179 (2007), 2999–3011.
78. 78 Yen, D., Cheung, J., Scheerens, H., et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 116 (2006), 1310–1316.
79. 79 Leon, A.J., Gomez, E., Garrote, J.A., et al. High levels of proinflammatory cytokines, but not markers of tissue injury, in unaffected intestinal areas from patients with IBD. Mediators Inflamm 2009 (2009), 1–10.
80. 80 Levy, A.M., Gleich, G.J., Sandborn, W.J., Tremaine, W.J., Steiner, B.L., Phillips, S.F., Increased eosinophil granule proteins in gut lavage fluid from patients with inflammatory bowel disease. Mayo Clin Proc 72 (1997), 117–123.
81. 81 Uguccioni, M., Gionchetti, P., Robbiani, D.F., et al. Increased expression of IP-10, IL-8, MCP-1, and MCP-3 in ulcerative colitis. Am J Pathol 155 (1999), 331–336.
82. 82 Mayer, L., Sandborn, W.J., Stepanov, Y., et al. Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Gut 63 (2014), 442–450.
83. 83 Del Zotto, B., Mumolo, G., Pronio, A.M., Montesani, C., Tersigni, R., Boirivant, M., TGF-beta1 production in inflammatory bowel disease: differing production patterns in Crohn's disease and ulcerative colitis. Clin Exp Immunol 134 (2003), 120–126.
84. 84 West, G.A., Matsuura, T., Levine, A.D., Klein, J.S., Fiocchi, C., Interleukin 4 in inflammatory bowel disease and mucosal immune reactivity. Gastroenterology 110 (1996), 1683–1695.
85. 85 Haas, S.L., Abbatista, M., Brade, J., Singer, M.V., Bocker, U., Interleukin-18 serum levels in inflammatory bowel diseases: correlation with disease activity and inflammatory markers. Swiss Med Wkly 139 (2009), 140–145.
86. 86 Keates, A.C., Castagliuolo, I., Cruickshank, W.W., et al. Interleukin 16 is up-regulated in Crohn's disease and participates in TNBS colitis in mice. Gastroenterology 119 (2000), 972–982.
87. 87 Kelly, P., Suibhne, T.N., O'Morain, C., O'Sullivan, M., Vitamin D status and cytokine levels in patients with Crohn's disease. Int J Vitam Nutr Res 81 (2011), 205–210.
88. 88 Ostvik, A.E., Granlund, A.V., Bugge, M., et al. Enhanced expression of CXCL10 in inflammatory bowel disease: potential role of mucosal toll-like receptor 3 stimulation. Inflamm Bowel Dis 19 (2013), 265–274.
89. 89 Allez, M., Tieng, V., Nakazawa, A., et al. CD4+NKG2D+ T cells in Crohn's disease mediate inflammatory and cytotoxic responses through MICA interactions. Gastroenterology 132 (2007), 2346–2358.
90. 90 Stuber, E., Buschenfeld, A., Luttges, J., Von Freier, A., Arendt, T., Folsch, U.R., The expression of OX40 in immunologically mediated diseases of the gastrointestinal tract (celiac disease, Crohn's disease, ulcerative colitis). Eur J Clin Invest 30 (2000), 594–599.
91. 91 Brenna, O., Bruland, T., Furnes, M.W., et al. The guanylate cyclase-C signaling pathway is down-regulated in inflammatory bowel disease. Scand J Gastroenterol 50 (2015), 1241–1252.
92. 92 Godkin, A.J., De Belder, A.J., Villa, L., et al. Expression of nitric oxide synthase in ulcerative colitis. Eur J Clin Invest 26 (1996), 867–872.
93. 93 Tarlton, J.F., Whiting, C.V., Tunmore, D., et al. The role of up-regulated serine proteases and matrix metalloproteinases in the pathogenesis of a murine model of colitis. Am J Pathol 157 (2000), 1927–1935.
94. 94 Meijer, M.J., Mieremet-Ooms, M.A., van der Zon, A.M., et al. Increased mucosal matrix metalloproteinase-1, -2, -3 and -9 activity in patients with inflammatory bowel disease and the relation with Crohn's disease phenotype. Dig Liver Dis 39 (2007), 733–739.
95. 95 Rafa, H., Saoula, H., Belkhelfa, M., et al. IL-23/IL-17A axis correlates with the nitric oxide pathway in inflammatory bowel disease: immunomodulatory effect of retinoic acid. J Interferon Cytokine Res 33 (2013), 355–368.
96. 96 Bustos, D., Negri, G., De Paula, J.A., et al. Colonic proteinases: increased activity in patients with ulcerative colitis. Medicina (B Aires) 58 (1998), 262–264.
97. 97 Midtvedt, T., Zabarovsky, E., Norin, E., et al. Increase of faecal tryptic activity relates to changes in the intestinal microbiome: analysis of Crohn's disease with a multidisciplinary platform. PLoS One, 8, 2013, e66074.
98. 98 Cario, E., Podolsky, D.K., Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 68 (2000), 7010–7017.
99. 99 Hart, A.L., Al-Hassi, H.O., Rigby, R.J., et al. Characteristics of intestinal dendritic cells in inflammatory bowel diseases. Gastroenterology 129 (2005), 50–65.
100. 100 Hu, S., Ciancio, M.J., Lahav, M., et al. Translational inhibition of colonic epithelial heat shock proteins by IFN-gamma and TNF-alpha in intestinal inflammation. Gastroenterology 133 (2007), 1893–1904.
101. 101 Vincent, F.B., Morand, E.F., Murphy, K., Mackay, F., Mariette, X., Marcelli, C., Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis 72 (2013), 165–178.
102. 102 Fuss, I.J., Heller, F., Boirivant, M., et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest 113 (2004), 1490–1497.
103. 103 Pullan, R.D., Thomas, G.A., Rhodes, M., et al. Thickness of adherent mucus gel on colonic mucosa in humans and its relevance to colitis. Gut 35 (1994), 353–359.
104. 104 Monteleone, G., Caruso, R., Pallone, F., Targets for new immunomodulation strategies in inflammatory bowel disease. Autoimmun Rev 13 (2014), 11–14.
105. 105 Danese, S., Rudzinski, J., Brandt, W., et al. Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study. Gut 64 (2015), 243–249.
106. 106 Reinisch, W., Panes, J., Khurana, S., et al. Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study. Gut 64 (2015), 894–900.
107. 107 Singh, U.P., Singh, S., Singh, R., Cong, Y., Taub, D.D., Lillard, J.W. Jr., CXCL10-producing mucosal CD4+ T cells, NK cells, and NKT cells are associated with chronic colitis in IL-10(−/−) mice, which can be abrogated by anti-CXCL10 antibody inhibition. J Interferon Cytokine Res 28 (2008), 31–43.
108. 108 Efficacy, Pharmacokinetics, Tolerability, Safety of SB012 Intrarectally Applied in Active Ulcerative Colitis Patients, 2015 www.clinicaltrials.gov/show/NCT02129439.
109. 109 Guo, H., Ingolia, N.T., Weissman, J.S., Bartel, D.P., Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466 (2010), 835–840.
110. 110 Boldin, M.P., Baltimore, D., MicroRNAs, new effectors and regulators of NF-kappaB. Immunol Rev 246 (2012), 205–220.
111. 111 Wu, F., Zikusoka, M., Trindade, A., et al. MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2 alpha. Gastroenterology 135 (2008), 1624–1635.e24.
112. 112 Koukos, G., Polytarchou, C., Kaplan, J.L., et al. MicroRNA-124 regulates STAT3 expression and is down-regulated in colon tissues of pediatric patients with ulcerative colitis. Gastroenterology 145 (2013), 842–852.e2.
113. 113 Polytarchou, C., Hommes, D.W., Palumbo, T., et al. MicroRNA214 is associated with progression of ulcerative colitis, and inhibition reduces development of colitis and colitis-associated cancer in mice. Gastroenterology 149 (2015), 981–992.e11.
114. 114 Tanaka, T., Grusby, M.J., Kaisho, T., PDLIM2-mediated termination of transcription factor NF-kappaB activation by intranuclear sequestration and degradation of the p65 subunit. Nat Immunol 8 (2007), 584–591.
115. 115 Romashkova, J.A., Makarov, S.S., NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 401 (1999), 86–90.
116. 116 Im, E., Jung, J., Pothoulakis, C., Rhee, S.H., Disruption of Pten speeds onset and increases severity of spontaneous colitis in Il10(−/−) mice. Gastroenterology 147 (2014), 667–679.e10.
117. 117 Kriegel, C., Amiji, M., Oral TNF-alpha gene silencing using a polymeric microsphere-based delivery system for the treatment of inflammatory bowel disease. J Control Release 150 (2011), 77–86.
118. 118 Wilson, D.S., Dalmasso, G., Wang, L., Sitaraman, S.V., Merlin, D., Murthy, N., Orally delivered thioketal nanoparticles loaded with TNF-alpha-siRNA target inflammation and inhibit gene expression in the intestines. Nat Mater 9 (2010), 923–928.
119. 119 McCarthy, J., O'Neill, M.J., Bourre, L., et al. Gene silencing of TNF-alpha in a murine model of acute colitis using a modified cyclodextrin delivery system. J Control Release 168 (2013), 28–34.
120. 120 Tsumura, H., Ito, M., Li, X.K., et al. The role of CD98hc in mouse macrophage functions. Cell Immunol 276 (2012), 128–134.
121. 121 Fais, S., Pallone, F., Ability of human colonic epithelium to express the 4F2 antigen, the common acute lymphoblastic leukemia antigen, and the transferrin receptor. Studies in inflammatory bowel disease and after in vitro exposure to different stimuli. Gastroenterology 97 (1989), 1435–1441.
122. 122 Kucharzik, T., Lugering, A., Yan, Y., et al. Activation of epithelial CD98 glycoprotein perpetuates colonic inflammation. Lab Invest 85 (2005), 932–941.
123. 123 Nguyen, H.T., Dalmasso, G., Yan, Y., et al. MicroRNA-7 modulates CD98 expression during intestinal epithelial cell differentiation. J Biol Chem 285 (2010), 1479–1489.
124. 124 Nguyen, H.T., Dalmasso, G., Torkvist, L., et al. CD98 expression modulates intestinal homeostasis, inflammation, and colitis-associated cancer in mice. J Clin Invest 121 (2011), 1733–1747.
125. 125 Laroui, H., Geem, D., Xiao, B., et al. Targeting intestinal inflammation with CD98 siRNA/PEI-loaded nanoparticles. Mol Ther 22 (2014), 69–80.
126. 126 Sugamura, K., Ishii, N., Weinberg, A.D., Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol 4 (2004), 420–431.
127. 127 Imura, A., Hori, T., Imada, K., et al. The human OX40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells. J Exp Med 183 (1996), 2185–2195.
128. 128 Higgin, L.M., McDonald, S.A., Whittle, N., Crockett, N., Shields, J.G., MacDonald, T.T., Regulation of T cell activation in vitro and in vivo by targeting the OX40-OX40 ligand interaction: amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40 ligand-IgG fusion protein. J Immunol 162 (1999), 486–493.
129. 129 Totsuka, T., Kanai, T., Uraushihara, K., et al. Therapeutic effect of anti-OX40L and anti-TNF-alpha MAbs in a murine model of chronic colitis. Am J Physiol Gastrointest Liver Physiol 284 (2003), G595–G603.
130. 130 Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis, 2016 www.clinicaltrials.gov/show/NCT02647866.
131. 131 Pitari, G.M., Pharmacology and clinical potential of guanylyl cyclase C agonists in the treatment of ulcerative colitis. Drug Des Devel Ther 7 (2013), 351–360.
132. 132 Forte, L.R. Jr., Uroguanylin and guanylin peptides: pharmacology and experimental therapeutics. Pharmacol Ther 104 (2004), 137–162.
133. 133 Han, X., Mann, E., Gilbert, S., et al. Loss of guanylyl cyclase C (GCC) signaling leads to dysfunctional intestinal barrier. PLoS One, 6, 2011, e16139.
134. 134 Shailubhai, K., Palejwala, V., Arjunan, K.P., et al. Plecanatide and dolcanatide, novel guanylate cyclase-C agonists, ameliorate gastrointestinal inflammation in experimental models of murine colitis. World J Gastrointest Pharmacol Ther 6 (2015), 213–222.
135. 135 Pizarro, T.T., Michie, M.H., Bentz, M., et al. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells. J Immunol 162 (1999), 6829–6835.
136. 136 Siegmund, B., Fantuzzi, G., Rieder, F., et al. Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha production. Am J Physiol Regul Integr Comp Physiol 281 (2001), R1264–R1273.
137. 137 Kimura, A., Kishimoto, T., IL-6: regulator of Treg/Th17 balance. Eur J Immunol 40 (2010), 1830–1835.
138. 138 Atreya, R., Mudter, J., Finotto, S., et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat Med 6 (2000), 583–588.
139. 139 Ito, H., Takazoe, M., Fukuda, Y., et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 126 (2004), 989–996 discussion 947.
140. 140 Scharl, M., Frei, S., Pesch, T., et al. Interleukin-13 and transforming growth factor beta synergise in the pathogenesis of human intestinal fistulae. Gut 62 (2013), 63–72.
141. 141 Wynn, T.A., IL-13 effector functions. Annu Rev Immunol 21 (2003), 425–456.
142. 142 A Phase II Efficacy Study in Fistulizing Crohn's Disease Patients, 2015 www.clinicaltrials.gov/show/NCT01355614.
143. 143 Monteleone, G., Monteleone, I., Fina, D., et al. Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease. Gastroenterology 128 (2005), 687–694.
144. 144 Fina, D., Sarra, M., Fantini, M.C., et al. Regulation of gut inflammation and th17 cell response by interleukin-21. Gastroenterology 134 (2008), 1038–1048.
145. 145 A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease, 2015 www.clinicaltrials.gov/show/NCT01751152.
146. 146 Ito, Y., Kanai, T., Totsuka, T., et al. Blockade of NKG2D signaling prevents the development of murine CD4+ T cell-mediated colitis. Am J Physiol Gastrointest Liver Physiol 294 (2008), G199–G207.
147. 147 Kjellev, S., Haase, C., Lundsgaard, D., Urso, B., Tornehave, D., Markholst, H., Inhibition of NKG2D receptor function by antibody therapy attenuates transfer-induced colitis in SCID mice. Eur J Immunol 37 (2007), 1397–1406.
148. 148 Safety and Efficacy of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease, 2014 www.clinicaltrials.gov/show/NCT01203631.
149. 149 Toussirot, E., The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases. Inflamm Allergy Drug Targets 11 (2012), 159–168.
150. 150 Wang, X., Wu, T., Zhou, F., et al. IL12p40 regulates functional development of human CD4+ T cells: enlightenment by the elevated expressions of IL12p40 in patients with inflammatory bowel diseases. Medicine (Baltimore), 94, 2015, e613.
151. 151 Neurath, M.F., Fuss, I., Kelsall, B.L., Stuber, E., Strober, W., Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 182 (1995), 1281–1290.
152. 152 Sarra, M., Pallone, F., Macdonald, T.T., Monteleone, G., IL-23/IL-17 axis in IBD. Inflamm Bowel Dis 16 (2010), 1808–1813.
153. 153 Sandborn, W.J., Feagan, B.G., Fedorak, R.N., et al. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 135 (2008), 1130–1141.
154. 154 Panaccione, R., Sandborn, W.J., Gordon, G.L., et al. Briakinumab for treatment of Crohn's disease: results of a randomized trial. Inflamm Bowel Dis 21 (2015), 1329–1340.
155. 155 Elson, C.O., Cong, Y., Weaver, C.T., et al. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology 132 (2007), 2359–2370.
156. 156 A Study of LY3074828 in Participants With Moderate to Severe Ulcerative Colitis, 2016 www.clinicaltrials.gov/show/NCT02589665.
157. 157 Gaffen, S.L., Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 9 (2009), 556–567.
158. 158 Khanna, R., Preiss, J.C., MacDonald, J.K., Timmer, A., Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease. Cochrane Database Syst Rev, 5, 2015, CD007572.
159. 159 Hueber, W., Sands, B.E., Lewitzky, S., et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61 (2012), 1693–1700.
160. 160 Ogawa, A., Andoh, A., Araki, Y., Bamba, T., Fujiyama, Y., Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice. Clin Immunol 110 (2004), 55–62.
161. 161 Colombel, J.F., Sendid, B., Jouault, T., Poulain, D., Secukinumab failure in Crohn's disease: the yeast connection?. Gut 62 (2013), 800–801.
162. 162 Breese, E., Braegger, C.P., Corrigan, C.J., Walker-Smith, J.A., MacDonald, T.T., Interleukin-2- and interferon-gamma-secreting T cells in normal and diseased human intestinal mucosa. Immunology 78 (1993), 127–131.
163. 163 Fuss, I.J., Neurath, M., Boirivant, M., et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 157 (1996), 1261–1270.
164. 164 Hommes, D.W., Mikhajlova, T.L., Stoinov, S., et al. Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut 55 (2006), 1131–1137.
165. 165 Barrett, K.E., Metcalfe, D.D., The mucosal mast cell and its role in gastrointestinal allergic diseases. Clin Rev Allergy 2 (1984), 39–53.
166. 166 Raithel, M., Winterkamp, S., Pacurar, A., Ulrich, P., Hochberger, J., Hahn, E.G., Release of mast cell tryptase from human colorectal mucosa in inflammatory bowel disease. Scand J Gastroenterol 36 (2001), 174–179.
167. 167 Nishida, Y., Murase, K., Isomoto, H., et al. Different distribution of mast cells and macrophages in colonic mucosa of patients with collagenous colitis and inflammatory bowel disease. Hepatogastroenterology 49 (2002), 678–682.
168. 168 Galli, S.J., Grimbaldeston, M., Tsai, M., Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. Nat Rev Immunol 8 (2008), 478–486.
169. 169 He, S.H., Key role of mast cells and their major secretory products in inflammatory bowel disease. World J Gastroenterol 10 (2004), 309–318.
170. 170 Marshall, J.K., Irvine, E.J., Ketotifen treatment of active colitis in patients with 5-aminosalicylate intolerance. Can J Gastroenterol 12 (1998), 273–275.
171. 171 Goldsmith, P., McGarity, B., Walls, A.F., Church, M.K., Millward-Sadler, G.H., Robertson, D.A., Corticosteroid treatment reduces mast cell numbers in inflammatory bowel disease. Dig Dis Sci 35 (1990), 1409–1413.
172. 172 Winterkamp, S., Raithel, M., Hahn, E.G., Secretion and tissue content of eosinophil cationic protein in Crohn's disease. J Clin Gastroenterol 30 (2000), 170–175.
173. 173 Midura-Kiela, M.T., Radhakrishnan, V.M., Larmonier, C.B., Laubitz, D., Ghishan, F.K., Kiela, P.R., Curcumin inhibits interferon-gamma signaling in colonic epithelial cells. Am J Physiol Gastrointest Liver Physiol 302 (2012), G85–G96.
174. 174 Singh, S., Aggarwal, B.B., Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem 270 (1995), 24995–25000.
175. 175 Chen, Y.R., Tan, T.H., Inhibition of the c-Jun N-terminal kinase (JNK) signaling pathway by curcumin. Oncogene 17 (1998), 173–178.
176. 176 Suh, H.W., Kang, S., Kwon, K.S., Curcumin attenuates glutamate-induced HT22 cell death by suppressing MAP kinase signaling. Mol Cell Biochem 298 (2007), 187–194.
177. 177 Xiao, B., Si, X., Zhang, M., Merlin, D., Oral administration of pH-sensitive curcumin-loaded microparticles for ulcerative colitis therapy. Colloids Surf B Biointerfaces 135 (2015), 379–385.
178. 178 Mascaraque, C., Aranda, C., Ocon, B., et al. Rutin has intestinal antiinflammatory effects in the CD4+ CD62L+ T cell transfer model of colitis. Pharmacol Res 90 (2014), 48–57.
179. 179 Wu, S.L., Chen, J.C., Li, C.C., Lo, H.Y., Ho, T.Y., Hsiang, C.Y., Vanillin improves and prevents trinitrobenzene sulfonic acid-induced colitis in mice. J Pharmacol Exp Ther 330 (2009), 370–376.
180. 180 Matsuda, C., Ito, T., Song, J., et al. Therapeutic effect of a new immunosuppressive agent, everolimus, on interleukin-10 gene-deficient mice with colitis. Clin Exp Immunol 148 (2007), 348–359.
181. 181 Park, S., Regmi, S.C., Park, S.Y., et al. Protective effect of 7-O-succinyl macrolactin A against intestinal inflammation is mediated through PI3-kinase/Akt/mTOR and NF-kappaB signaling pathways. Eur J Pharmacol 735 (2014), 184–192.
182. 182 Xiao, H.T., Lin, C.Y., Ho, D.H., et al. Inhibitory effect of the gallotannin corilagin on dextran sulfate sodium-induced murine ulcerative colitis. J Nat Prod 76 (2013), 2120–2125.
183. 183 Terajima, M., Inoue, T., Magari, K., Yamazaki, H., Higashi, Y., Mizuhara, H., Anti-inflammatory effect and selectivity profile of AS1940477, a novel and potent p38 mitogen-activated protein kinase inhibitor. Eur J Pharmacol 698 (2013), 455–462.
184. 184 Kankuri, E., Hamalainen, M., Hukkanen, M., et al. Suppression of pro-inflammatory cytokine release by selective inhibition of inducible nitric oxide synthase in mucosal explants from patients with ulcerative colitis. Scand J Gastroenterol 38 (2003), 186–192.
185. 185 Singh, K., Chaturvedi, R., Barry, D.P., et al. The apolipoprotein E-mimetic peptide COG112 inhibits NF-kappaB signaling, proinflammatory cytokine expression, and disease activity in murine models of colitis. J Biol Chem 286 (2011), 3839–3850.
186. 186 Singer, M., Trugnan, G., Chelbi-Alix, M.K., Arsenic trioxide reduces 2,4,6-trinitrobenzene sulfonic acid-induced murine colitis via nuclear factor-kappaB down-regulation and caspase-3 activation. Innate Immun 17 (2011), 365–374.
187. 187 Keerthy, H.K., Mohan, C.D., Siveen, K.S., et al. Novel synthetic biscoumarins target tumor necrosis factor-alpha in hepatocellular carcinoma in vitro and in vivo. J Biol Chem 289 (2014), 31879–31890.
188. 188 Dotan, I., Rachmilewitz, D., Schreiber, S., et al. A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease. Gut 59 (2010), 760–766.
189. 189 Arab, H.H., Al-Shorbagy, M.Y., Abdallah, D.M., Nassar, N.N., Telmisartan attenuates colon inflammation, oxidative perturbations and apoptosis in a rat model of experimental inflammatory bowel disease. PLoS One, 9, 2014, e97193.
190. 190 Yan, F., Cao, H., Cover, T.L., Whitehead, R., Washington, M.K., Polk, D.B., Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth. Gastroenterology 132 (2007), 562–575.
191. 191 Bousvaros, A., Guandalini, S., Baldassano, R.N., et al. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm Bowel Dis 11 (2005), 833–839.
192. 192 Mennigen, R., Nolte, K., Rijcken, E., et al. Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis. Am J Physiol Gastrointest Liver Physiol 296 (2009), G1140–G1149.
193. 193 Tursi, A., Brandimarte, G., Papa, A., et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 105 (2010), 2218–2227.
194. 194 A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease, 2014 www.clinicaltrials.gov/show/NCT01632462.
195. 195 Kruis, W., Fric, P., Pokrotnieks, J., et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53 (2004), 1617–1623.
196. 196 Vandenbroucke, K., de Haard, H., Beirnaert, E., et al. Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis. Mucosal Immunol 3 (2010), 49–56.
197. 197 Braat, H., Rottiers, P., Hommes, D.W., et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol 4 (2006), 754–759.
198. 198 Hayashi, A., Sato, T., Kamada, N., et al. A single strain of Clostridium butyricum induces intestinal IL-10-producing macrophages to suppress acute experimental colitis in mice. Cell Host Microbe 13 (2013), 711–722.
199. 199 Thomas, S., Metzke, D., Schmitz, J., Dorffel, Y., Baumgart, D.C., Anti-inflammatory effects of Saccharomyces boulardii mediated by myeloid dendritic cells from patients with Crohn's disease and ulcerative colitis. Am J Physiol Gastrointest Liver Physiol 301 (2011), G1083–G1092.
200. 200 Selvam, R., Maheswari, P., Kavitha, P., Ravichandran, M., Sas, B., Ramchand, C.N., Effect of Bacillus subtilis PB6, a natural probiotic on colon mucosal inflammation and plasma cytokines levels in inflammatory bowel disease. Indian J Biochem Biophys 46 (2009), 79–85.
201. 201 Zhang, M., Qiu, X., Zhang, H., et al. Faecalibacterium prausnitzii inhibits interleukin-17 to ameliorate colorectal colitis in rats. PLoS One, 9, 2014, e109146.
202. 202 Nishitani, Y., Tanoue, T., Yamada, K., et al. Lactococcus lactis subsp. Cremoris FC alleviates symptoms of colitis induced by dextran sulfate sodium in mice. Int Immunopharmacol 9 (2009), 1444–1451.
203. 203 Lee, J.H., Lee, B., Lee, H.S., et al. Lactobacillus suntoryeus inhibits pro-inflammatory cytokine expression and TLR-4-linked NF-kappaB activation in experimental colitis. Int J Colorectal Dis 24 (2009), 231–237.
204. 204 Matsumoto, S., Hara, T., Nagaoka, M., et al. A component of polysaccharide peptidoglycan complex on lactobacillus induced an improvement of murine model of inflammatory bowel disease and colitis-associated cancer. Immunology 128 (2009), e170–e180.
205. 205 Borody, T.J., Khoruts, A., Fecal microbiota transplantation and emerging applications. Nat Rev Gastroenterol Hepatol 9 (2012), 88–96.
206. 206 van Nood, E., Vrieze, A., Nieuwdorp, M., et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 368 (2013), 407–415.
207. 207 Borody, T.J., Warren, E.F., Leis, S., Surace, R., Ashman, O., Treatment of ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol 37 (2003), 42–47.
208. 208 Cui, B., Feng, Q., Wang, H., et al. Fecal microbiota transplantation through mid-gut for refractory Crohn's disease: safety, feasibility, and efficacy trial results. J Gastroenterol Hepatol 30 (2015), 51–58.
209. 209 Cammarota, G., Ianiro, G., Cianci, R., Bibbo, S., Gasbarrini, A., Curro, D., The involvement of gut microbiota in inflammatory bowel disease pathogenesis: potential for therapy. Pharmacol Ther 149 (2015), 191–212.
210. 210 Moayyedi, P., Surette, M.G., Kim, P.T., et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 149 (2015), 102–109.e6.
211. 211 Vermeire, S., Joossens, M., Verbeke, K., et al. Donor species richness determines faecal microbiota transplantation success in inflammatory bowel disease. J Crohns Colitis 10 (2016), 387–394.
212. 212 Erickson, A.R., Cantarel, B.L., Lamendella, R., et al. Integrated metagenomics/metaproteomics reveals human host-microbiota signatures of Crohn's disease. PLoS One, 7, 2012, e49138.
213. 213 Borody, T.J., George, L., Andrews, P., et al. Bowel-flora alteration: a potential cure for inflammatory bowel disease and irritable bowel syndrome?. Med J Aust, 150, 1989, 604.
214. 214 Vermeire, S., Joossens, M., Verbeke, K., et al. Sa1922 pilot study on the safety and efficacy of faecal microbiota transplantation in refractory Crohn's disease. Gastroenterology 142 (2012), S–360.
215. 215 Janeway, C.A. Jr., Medzhitov, R., Innate immune recognition. Annu Rev Immunol 20 (2002), 197–216.
216. 216 Cario, E., Rosenberg, I.M., Brandwein, S.L., Beck, P.L., Reinecker, H.C., Podolsky, D.K., Lipopolysaccharide activates distinct signaling pathways in intestinal epithelial cell lines expressing toll-like receptors. J Immunol 164 (2000), 966–972.
217. 217 Cario, E., Gerken, G., Podolsky, D.K., Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function. Gastroenterology 132 (2007), 1359–1374.
218. 218 Pierik, M., Joossens, S., Van Steen, K., et al. Toll-like receptor-1, -2, and -6 polymorphisms influence disease extension in inflammatory bowel diseases. Inflamm Bowel Dis 12 (2006), 1–8.
219. 219 Park, B.S., Song, D.H., Kim, H.M., Choi, B.S., Lee, H., Lee, J.O., The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 458 (2009), 1191–1195.
220. 220 Ungaro, R., Fukata, M., Hsu, D., et al. A novel toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis. Am J Physiol Gastrointest Liver Physiol 296 (2009), G1167–G1179.
221. 221 Monteleone, G., Kumberova, A., Croft, N.M., McKenzie, C., Steer, H.W., MacDonald, T.T., Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest 108 (2001), 601–609.
222. 222 Boirivant, M., Pallone, F., Di Giacinto, C., et al. Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-beta1-mediated suppression of colitis. Gastroenterology 131 (2006), 1786–1798.
223. 223 Monteleone, G., Neurath, M.F., Ardizzone, S., et al. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. N Engl J Med 372 (2015), 1104–1113.
224. 224 Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease, 2016 www.clinicaltrials.gov/show/NCT02596893.
225. 225 Fedorak, R.N., Gangl, A., Elson, C.O., et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The interleukin 10 inflammatory bowel disease cooperative study group. Gastroenterology 119 (2000), 1473–1482.
226. 226 Wadwa, M., Klopfleisch, R., Adamczyk, A., et al. IL-10 downregulates CXCR3 expression on Th1 cells and interferes with their migration to intestinal inflammatory sites. Mucosal Immunol, 2016.
227. 227 Xiong, J., Lin, Y.H., Bi, L.H., Wang, J.D., Bai, Y., Liu, S.D., Effects of interleukin-4 or interleukin-10 gene therapy on trinitrobenzenesulfonic acid-induced murine colitis. BMC Gastroenterol, 13, 2013, 165.
228. 228 van Deen, W.K., Oikonomopoulos, A., Hommes, D.W., Stem cell therapy in inflammatory bowel disease: which, when and how?. Curr Opin Gastroenterol 29 (2013), 384–390.
229. 229 Ditschkowski, M., Einsele, H., Schwerdtfeger, R., et al. Improvement of inflammatory bowel disease after allogeneic stem-cell transplantation. Transplantation 75 (2003), 1745–1747.
230. 230 Hawkey, C.J., Allez, M., Clark, M.M., et al. Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA 314 (2015), 2524–2534.
231. 231 Garcia-Bosch, O., Ricart, E., Panes, J., Review article: stem cell therapies for inflammatory bowel disease—efficacy and safety. Aliment Pharmacol Ther 32 (2010), 939–952.
232. 232 Garcia-Olmo, D., Herreros, D., Pascual, I., et al. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis Colon Rectum 52 (2009), 79–86.
233. 233 de la Portilla, F., Alba, F., Garcia-Olmo, D., Herrerias, J.M., Gonzalez, F.X., Galindo, A., Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn's disease: results from a multicenter phase I/IIa clinical trial. Int J Colorectal Dis 28 (2013), 313–323.
234. 234 Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease (ADMIRE-CD), 2015 www.clinicaltrials.gov/show/NCT01541579.
235. 235 Allogeneic Adipose Tissue-derived Mesenchymal Stem Cells for the Induction of Remission in Ulcerative Colitis (ALOASCU), 2013 www.clinicaltrials.gov/show/NCT01914887.
236. 236 Mannon, P.J., Remestemcel-L: human mesenchymal stem cells as an emerging therapy for Crohn's disease. Expert Opin Biol Ther 11 (2011), 1249–1256.
237. 237 Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease, 2015 www.clinicaltrials.gov/show/NCT01233960.
238. 238 Vaes, B., Van't Hof, W., Deans, R., Pinxteren, J., Application of multiStem((R)) allogeneic cells for immunomodulatory therapy: clinical progress and pre-clinical challenges in prophylaxis for graft versus host disease. Front Immunol, 3, 2012, 345.
239. 239 A Study to Investigate the Safety and Possible Clinical Benefit of Multistem in Patients With Moderate to Severe Ulcerative Colitis, 2015 www.clinicaltrials.gov/show/NCT01240915.
240. 240 Bonen, D.K., Cho, J.H., The genetics of inflammatory bowel disease. Gastroenterology 124 (2003), 521–536.
241. 241 Brittan, M., Alison, M.R., Schier, S., Wright, N.A., Bone marrow stem cell-mediated regeneration in IBD: where do we go from here?. Gastroenterology 132 (2007), 1171–1173.
242. 242 Ochi, H., Abraham, M., Ishikawa, H., et al. Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+ CD25- LAP+ T cells. Nat Med 12 (2006), 627–635.
243. 243 Forster, K., Goethel, A., Chan, C.W., Zanello, G., Streutker, C., Croitoru, K., An oral CD3-specific antibody suppresses T-cell-induced colitis and alters cytokine responses to T-cell activation in mice. Gastroenterology 143 (2012), 1298–1307.
244. 244 Oral OKT3 for the Treatment of Active Ulcerative Colitis, 2013 www.clinicaltrials.gov/show/NCT01287195.
245. 245 Ulcerative Colitis Study: Study of Visilizumab in Patients With Severe Ulcerative Colitis, 2012 www.clinicaltrials.gov/show/NCT00267306.
246. 246 Visilizumab for Moderate to Severe Inflammatory, Nonstricturing, Nonpenetrating Crohn's Disease, 2012 www.clinicaltrials.gov/show/NCT00267722.
247. 247 Sandborn, W.J., Colombel, J.F., Frankel, M., et al. Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis. Gut 59 (2010), 1485–1492.
248. 248 Brown, J.B., Lee, G., Grimm, G.R., Barrett, T.A., Therapeutic benefit of pentostatin in severe IL-10−/− colitis. Inflamm Bowel Dis 14 (2008), 880–887.
249. 249 Hausmann, M., Spöttl, T., Andus, T., et al. Subtractive screening reveals up-regulation of NADPH oxidase expression in Crohn's disease intestinal macrophages. Clin Exp Immunol 125 (2001), 48–55.
250. 250 Hausmann, M., Obermeier, F., Paper, D.H., et al. In vivo treatment with the herbal phenylethanoid acteoside ameliorates intestinal inflammation in dextran sulphate sodium-induced colitis. Clin Exp Immunol 148 (2007), 373–381.
251. 251 Sakthivel, K.M., Guruvayoorappan, C., Protective effect of Acacia ferruginea against ulcerative colitis via modulating inflammatory mediators, cytokine profile and NF-kappaB signal transduction pathways. J Environ Pathol Toxicol Oncol 33 (2014), 83–98.
252. 252 V, V.P., C, G., Protective effect of marine mangrove Rhizophora apiculata on acetic acid induced experimental colitis by regulating anti-oxidant enzymes, inflammatory mediators and nuclear factor-kappa B subunits. Int Immunopharmacol 18 (2014), 124–134.
253. 253 Kumar, V.S., Rajmane, A.R., Adil, M., Kandhare, A.D., Ghosh, P., Bodhankar, S.L., Naringin ameliorates acetic acid induced colitis through modulation of endogenous oxido-nitrosative balance and DNA damage in rats. J Biomed Res 28 (2014), 132–145.
254. 254 Sakthivel, K.M., Guruvayoorappan, C., Amentoflavone inhibits iNOS, COX-2 expression and modulates cytokine profile, NF-kappaB signal transduction pathways in rats with ulcerative colitis. Int Immunopharmacol 17 (2013), 907–916.
255. 255 Nagib, M.M., Tadros, M.G., ElSayed, M.I., Khalifa, A.E., Anti-inflammatory and anti-oxidant activities of olmesartan medoxomil ameliorate experimental colitis in rats. Toxicol Appl Pharmacol 271 (2013), 106–113.
256. 256 Philippe, D., Brahmbhatt, V., Foata, F., et al. Anti-inflammatory effects of Lacto-Wolfberry in a mouse model of experimental colitis. World J Gastroenterol 18 (2012), 5351–5359.
257. 257 Yao, J., Wang, J.Y., Liu, L., et al. Anti-oxidant effects of resveratrol on mice with DSS-induced ulcerative colitis. Arch Med Res 41 (2010), 288–294.
258. 258 Lan, A., Blachier, F., Benamouzig, R., et al. Mucosal healing in inflammatory bowel diseases: is there a place for nutritional supplementation?. Inflamm Bowel Dis 21 (2015), 198–207.
259. 259 Liu, X., Beaumont, M., Walker, F., et al. Beneficial effects of an amino acid mixture on colonic mucosal healing in rats. Inflamm Bowel Dis 19 (2013), 2895–2905.
260. 260 Hou, Y.C., Wu, J.M., Wang, M.Y., et al. Glutamine supplementation attenuates expressions of adhesion molecules and chemokine receptors on T cells in a murine model of acute colitis. Mediators Inflamm, 2014, 2014, 837107.
261. 261 Xue, H., Sufit, A.J., Wischmeyer, P.E., Glutamine therapy improves outcome of in vitro and in vivo experimental colitis models. JPEN J Parenter Enteral Nutr 35 (2011), 188–197.
262. 262 Crespo, I., San-Miguel, B., Prause, C., et al. Glutamine treatment attenuates endoplasmic reticulum stress and apoptosis in TNBS-induced colitis. PLoS One, 7, 2012, e50407.
263. 263 Kretzmann, N.A., Fillmann, H., Mauriz, J.L., et al. Effects of glutamine on proinflammatory gene expression and activation of nuclear factor kappa B and signal transducers and activators of transcription in TNBS-induced colitis. Inflamm Bowel Dis 14 (2008), 1504–1513.
264. 264 Kim, C.J., Kovacs-Nolan, J., Yang, C., Archbold, T., Fan, M.Z., Mine, Y., L-cysteine supplementation attenuates local inflammation and restores gut homeostasis in a porcine model of colitis. Biochim Biophys Acta 1790 (2009), 1161–1169.
265. 265 Coburn, L.A., Gong, X., Singh, K., et al. L-arginine supplementation improves responses to injury and inflammation in dextran sulfate sodium colitis. PLoS One, 7, 2012, e33546.
266. 266 Requena, P., Daddaoua, A., Martinez-Plata, E., et al. Bovine glycomacropeptide ameliorates experimental rat ileitis by mechanisms involving downregulation of interleukin 17. Br J Pharmacol 154 (2008), 825–832.
267. 267 Chen, Q., Wang, H., Zhu, C., Yan, Y., Pang, G., Anti-apoptotic effects of milk-derived casein glycomacropeptide on mice with ulcerative colitis. Food and Agricultural Immunology 25 (2014), 453–466.
268. 268 Wernlund, P.G., Hvas, C.L., Christensen, L.A., et al. MON-PP058: randomised clinical trial: casein glycomacropeptide for active distal ulcerative colitis—a pilot study. Clinical Nutrition, 34, 2015, S149.
269. 269 Gallowitsch-Puerta, M., Tracey, K.J., Immunologic role of the cholinergic anti-inflammatory pathway and the nicotinic acetylcholine alpha 7 receptor. Ann N Y Acad Sci 1062 (2005), 209–219.
270. 270 Borovikova, L.V., Ivanova, S., Zhang, M., et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 405 (2000), 458–462.